
Atara Biotherapeutics
(NASDAQ) ATRA
Atara Biotherapeutics Financials at a Glance
Market Cap
$35.33M
Revenue (TTM)
$120.77M
Net Income (TTM)
$32.69M
EPS (TTM)
$2.91
P/E Ratio
1.48
Dividend
$0.00
Beta (Volatility)
2.15 (High)
Dividend
$0.00
Beta (Volatility)
2.15 (High)
Price
$4.35
Volume
888
Open
$4.51
Price
$4.35
Volume
888
Open
$4.51
Previous Close
$4.35
Daily Range
$4.35 - $4.51
52-Week Range
$3.92 - $19.14
Dividend
$0.00
Beta (Volatility)
2.15 (High)
Price
$4.35
Volume
888
Open
$4.51
Previous Close
$4.35
Daily Range
$4.35 - $4.51
52-Week Range
$3.92 - $19.14
ATRA News
ATRA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Atara Biotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
14
CEO
Anhco Nguyen, PhD
Website
www.atarabio.comHeadquarters
South San Francisco, CA 94080, US
ATRA Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
30%
Net Income Margin
27%
Return on Equity
0%
Return on Capital
7%
Return on Assets
2%
Earnings Yield
67.57%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$35.33M
Shares Outstanding
8.18M
Volume
888
Short Interest
0.00%
Avg. Volume
449.78K
Financials (TTM)
Gross Profit
$99.56M
Operating Income
$35.86M
EBITDA
$50.41M
Operating Cash Flow
$50.94M
Capital Expenditure
$0.00
Free Cash Flow
$50.94M
Cash & ST Invst.
$8.48M
Total Debt
$52.80M
Atara Biotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.59M
-95.1%
Gross Profit
$1.49M
-94.3%
Gross Margin
93.48%
N/A
Market Cap
$35.33M
N/A
Market Cap/Employee
$230.91K
N/A
Employees
153
N/A
Net Income
$3.41M
+73.2%
EBITDA
$3.82M
+64.0%
Quarterly Fundamentals
Net Cash
$44.32M
-3219.6%
Accounts Receivable
$1.25M
-15.5%
Inventory
$0.00
-100.0%
Long Term Debt
$42.02M
+40.5%
Short Term Debt
$10.78M
-22.6%
Return on Assets
1.62%
N/A
Return on Invested Capital
6.75%
N/A
Free Cash Flow
$5.70M
+76.8%
Operating Cash Flow
$5.70M
+76.7%


![Biotech_Stocks_Step_1_Good_Data,_Step_2_Raise_Capital[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F605702%2Fbiotech_stocks_step_1_good_data_step_2_raise_capital1.jpg&w=3840&op=resize)




